Quotes: MENA   Enter Symbol: NewsLetter: Search: advanced

Promethera(R)Biosciences welcomes Frank Hazevoets as chief financial officer  Join our daily free Newsletter

MENAFN Press - 13/05/2014
No. of Ratings : 0
Add to Mixx!



(MENAFN Press) Promethera(R) Biosciences, an innovative orphan drug therapy company that develops stem cell therapies for the treatment of liver diseases, today announces that Frank Hazevoets has joined the company to lead its finance and administration team. Frank joined Promethera Biosciences SA on May 1, 2014 as chief financial officer (CFO). He will be based at the head office in Mont-Saint-Guibert, Belgium.

Frank Hazevoets is a highly experienced senior financial executive with over twenty five years international business experience. He trained at the Catholic University of Leuven (KUL) in Belgium as a commercial engineer and also obtained a masters degree in Artificial Intelligence and Cognitive Science. He has worked in leading positions in corporate finance and investment banking, strategy and business development. During his six years as CFO at Tigenix, he supported the company in its funding and growth strategy and helped them to obtain the first European marketing authorization for cell-based medicinal products in Europe.

"We are delighted that Frank is joining Promethera Biosciences as CFO," said Eric Halioua, chief executive officer. "He is going to play a key role in assisting our future development. Frank Hazevoets has the experience and expertise to strengthen the management team and to prepare the next strategic options at Promethera Biosciences. He will build the finance department to further support the future growth of Promethera(R)."

"I am really looking forward to working with the experienced team at Promethera and to sharing my expertise with them," said Frank Hazevoets, chief financial officer of Promethera Biosciences. "This company has the potential to become one of the leading orphan drug companies in the world. Many patients will benefit from their lead in developing and commercializing innovative cell and orphan therapy products based on propriary technologies."


About Promethera Biosciences:

Promethera Biosciences is a pharmaceutical company that develops innovative therapies for the treatment of orphan liver diseases. It is currently developing two products based on human liver progenitor cells:

Promethera(R) HepaStem is a cell therapy product based on the use of allogeneic stem cells isolated from healthy adult human livers (Heterologous Human Adult Liver Progenitor Cells, HHALPC). These cells can be used to treat a wide variety of liver diseases, from rare inborn metabolic diseases (which can be classified as 'orphan diseases' and mainly affecting children), to acquired deficiencies affecting adults, such as acute-on chronic liver diseases or liver fibrosis. HepaStem is currently tested in phase I/II clinical trial in Europe and Israel for the treatment of two orphan indications.

Promethera(R) H2Screen and H3Screen is a non-therapeutic in vitro product, based on a recently discovered and patented liver progenitor cell type, isolated from healthy adult human livers. This novel biotechnology tool is designed for early preclinical pharmaco-toxicological evaluation of drug candidates and new chemical entities.

Promethera Biosciences is a spin-off of the Universite Catholique de Louvain (UCL), founded in 2009. The company emerged from the lab of Professor Etienne Sokal, a leading expert in pediatric liver disease and cell. Promethera Biosciences is located in Mont-Saint-Guibert (Belgium).

Since its creation in 2009, Promethera Biosciences has raised EUR 34 million in two financial rounds, in capital, grants and loans from the Walloon Region. The main investors are Vesalius Biocapital, Mitsui Global Investment, BI Venture Fund, Shire and SRIW.

Promethera Biosciences has 47 employees led by an experienced management team.

For more information, please visit http://www.promethera.com


About Promethera(R)
Promethera(R)

 


MENAFN Press




  MENA News Headlines
 Sep 30 2016 - Italy's Eni confirms renewable energy deal with EgyptMENAFN
(MENAFN) Italian oil Eni agreed a common strategy with Egypt to construct renewable energy projects in the country.Moreover, the first project will be a solar plant in Sinai with output of 50 MW, ...

 Sep 30 2016 - Oman's budget deficit reaches USD10.83bn in H1MENAFN
(MENAFN) Oman's budget deficit increased and crossed the RO4bn mark for Jan-July period this year as government revenue continued to hurt by weak oil prices.Meanwhile, the deficit grew by 68 percent ...

 Sep 30 2016 - UAE hotels to cut costs by 20pctMENAFN
(MENAFN) Hotels in the UAE could cut their costs by more than 20 percent by reducing their energy and water consumption.Moreover, hotels with poor environmental policies consume three times more ...

 Sep 29 2016 - Kimberly process chair steps up momentum on Africa initiativeMENAFN Press
(MENAFN Press) Zimbabwe was the next stop on his extensive tour of African States, to give Africa a Voice, for which the Kimberley Process was originally intended. In Harare, the KP Chair met with ...

 Sep 29 2016 - Global Virtual Reality Market 2016 Share, Trend, Segmentation and Forecast To 2020MENAFN Press
(MENAFN Press) Global Virtual Reality Market 2016 Share, Trend, Segmentation and Forecast To 2020 next five years in an average of 106% CAGR; by 2020 over 430 billion products will be sold, and 21 ...

 Sep 29 2016 - NY Gov. Cuomo's Justice Center a Corruption SchemeMENAFN Press
(MENAFN Press) NY Gov. Cuomo's Justice Center a Corruption Scheme Jonathan Carey "Champion for the Disabled" Born September 12,1993 Killed by caregivers on February 15,2007 The corruption is ...

 Sep 29 2016 - Solving the last jigsaws to minimize risks, optimize costs and accelerate commercialization at Biosimilars North AmericaMENAFN Press
(MENAFN Press) Solving the last jigsaws to minimize risks, optimize costs and accelerate commercialization at Biosimilars North America The 3rd annual Biosimilars North America by popular demand, ...

 Sep 29 2016 - Haptic Interface Market 2016 market Share, Current and Future Players, Analysis and Forecast to 2022.MENAFN Press
(MENAFN Press) Haptic Interface Market 2016 market Share, Current and Future Players, Analysis and Forecast to 2022. Global Haptic Interface Market Information, by Components (Hardware, Software), ...

 Sep 29 2016 - Cold Forging Machine: Consumption, Demand, Sales, Competitor and Forecast 2016 2021MENAFN Press
(MENAFN Press) Cold Forging Machine: Consumption, Demand, Sales, Competitor and Forecast 2016 – 2021 Cold Forging Machine Global Market 2016 Analysis and Forecast to 2021 PUNE, INDIA, September ...

 Sep 29 2016 - Global Wind Power Market Top Manufactures, Market Demands, Trends, Industry Growth Analysis & Forecast 2021MENAFN Press
(MENAFN Press) Global Wind Power Market Top Manufactures, Market Demands, Trends, Industry Growth Analysis & Forecast 2021 Global Wind Power Market Information Report by Application (Residential ...

more...


 





Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country

Search News
Market Indices
Quotes & Charts

Global Indices
Arab Indices

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Economic Calendar
Financial Glossary


Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2014 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help